EP3720470A4 - Il-2 muteins and uses thereof - Google Patents

Il-2 muteins and uses thereof Download PDF

Info

Publication number
EP3720470A4
EP3720470A4 EP18887098.4A EP18887098A EP3720470A4 EP 3720470 A4 EP3720470 A4 EP 3720470A4 EP 18887098 A EP18887098 A EP 18887098A EP 3720470 A4 EP3720470 A4 EP 3720470A4
Authority
EP
European Patent Office
Prior art keywords
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18887098.4A
Other languages
German (de)
French (fr)
Other versions
EP3720470A1 (en
Inventor
Nathan HIGGINSON-SCOTT
Joanne L. Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,875 external-priority patent/US10174091B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of EP3720470A1 publication Critical patent/EP3720470A1/en
Publication of EP3720470A4 publication Critical patent/EP3720470A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP18887098.4A 2017-12-06 2018-11-28 Il-2 muteins and uses thereof Pending EP3720470A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Publications (2)

Publication Number Publication Date
EP3720470A1 EP3720470A1 (en) 2020-10-14
EP3720470A4 true EP3720470A4 (en) 2021-09-15

Family

ID=66751187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18887098.4A Pending EP3720470A4 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Country Status (11)

Country Link
EP (1) EP3720470A4 (en)
JP (1) JP7250790B2 (en)
KR (2) KR20200097275A (en)
CN (1) CN111432831A (en)
AU (1) AU2018378078A1 (en)
BR (1) BR112020011343A2 (en)
CA (1) CA3083941A1 (en)
IL (1) IL274844A (en)
MX (1) MX2020005208A (en)
SG (1) SG11202003965VA (en)
WO (1) WO2019112854A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. Madcam targeted immunotolerance
TW202124437A (en) * 2019-08-19 2021-07-01 美商潘迪恩營運公司 Targeted immunotolerance with a pd-1 agonist
CN114853874A (en) * 2019-09-10 2022-08-05 中国医学科学院北京协和医院 Long-acting interleukin-2 of target regulatory T cell and application thereof in treating autoimmune disease
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CN112358540A (en) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 Production method of recombinant IL2 in pichia pastoris
TW202345889A (en) * 2022-03-03 2023-12-01 大陸商海南先聲藥業有限公司 Pharmaceutical compositions of il2 mutant-antibody fc segment fusion proteins and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (en) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 Purification of recombinant interleukin-2
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP3211001B1 (en) * 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
JP2014518198A (en) * 2011-05-31 2014-07-28 ノヴォ ノルディスク アー／エス Epitope of IL-21 and IL-21 ligand
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
DK3172227T3 (en) * 2014-07-21 2019-12-02 Delinia Inc Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (en) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation
EP3606947B1 (en) * 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
WO2019112852A1 (en) 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance

Also Published As

Publication number Publication date
IL274844A (en) 2020-07-30
CN111432831A (en) 2020-07-17
SG11202003965VA (en) 2020-06-29
MX2020005208A (en) 2020-08-20
EP3720470A1 (en) 2020-10-14
JP2021507690A (en) 2021-02-25
CA3083941A1 (en) 2019-06-13
JP7250790B2 (en) 2023-04-03
AU2018378078A1 (en) 2020-06-18
BR112020011343A2 (en) 2020-11-17
KR20200097275A (en) 2020-08-18
WO2019112854A1 (en) 2019-06-13
KR20240039201A (en) 2024-03-26

Similar Documents

Publication Publication Date Title
EP3720470A4 (en) Il-2 muteins and uses thereof
EP3681888A4 (en) Pyrazolopyrimidinone compounds and uses thereof
EP3733693A4 (en) Il-2 variant
EP3720502A4 (en) Cytobiologics and therapeutic uses thereof
EP3453401A4 (en) Interleukin combination and use thereof
EP3758778A4 (en) Medical devices and uses thereof
EP3841096A4 (en) Pyridinylmethylenepiperidine derivatives and uses thereof
EP3511407A4 (en) Christensenella intestinihominis and application thereof
EP3902530A4 (en) Polymeric nanovaccines and uses thereof
EP3638251A4 (en) Bisphosphocin gel formulations and uses thereof
EP3700934A4 (en) Compounds and uses thereof
EP3687501A4 (en) Iniparib formulations and uses thereof
EP3808357A4 (en) Composition and uses thereof
EP3762364A4 (en) Pyrrolidineamide derivatives and uses thereof
EP3691629A4 (en) Nutrient-spore formulations and uses thereof
EP3730565A4 (en) Multilayer structure and uses thereof
EP3683303A4 (en) Megamonas funiformis and applications thereof
EP3856755A4 (en) Terpinoid derivatives and uses thereof
EP3746077A4 (en) Parenteral formulations and uses thereof
EP3665191A4 (en) Braf-specific tcrs and uses thereof
EP3689887A4 (en) Composition and light-emitting device using same
EP3729351A4 (en) Fast and partition-resilient blockchains
EP3684796A4 (en) Succinate-regulating polypeptides and use thereof
EP3635324A4 (en) Inverse-freezing compositions and use thereof
EP3611181A4 (en) Atp1a1-targeting polypeptide and use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISWESWARAIAH, JYOTHSNA

Inventor name: SAMPSON, ERIK ROBERT

Inventor name: OTIPOBY, KEVIN LEWIS

Inventor name: VINEY, JOANNE L.

Inventor name: HIGGINSON-SCOTT, NATHAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANDION OPERATIONS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039617

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101ALI20210809BHEP

Ipc: A61P 37/04 20060101ALI20210809BHEP

Ipc: A61P 37/02 20060101ALI20210809BHEP

Ipc: A61P 29/00 20060101ALI20210809BHEP

Ipc: A61K 47/68 20170101ALI20210809BHEP

Ipc: A61K 38/20 20060101AFI20210809BHEP